Literature DB >> 25113746

A murine model of neurofibromatosis type 2 that accurately phenocopies human schwannoma formation.

Jeffrey R Gehlhausen1, Su-Jung Park1, Ann E Hickox2, Matthew Shew3, Karl Staser1, Steven D Rhodes4, Keshav Menon3, Jacquelyn D Lajiness1, Muithi Mwanthi5, Xianlin Yang3, Jin Yuan3, Paul Territo6, Gary Hutchins6, Grzegorz Nalepa1, Feng-Chun Yang4, Simon J Conway7, Michael G Heinz2, Anat Stemmer-Rachamimov8, Charles W Yates9, D Wade Clapp10.   

Abstract

Neurofibromatosis type 2 (NF2) is an autosomal dominant genetic disorder resulting from germline mutations in the NF2 gene. Bilateral vestibular schwannomas, tumors on cranial nerve VIII, are pathognomonic for NF2 disease. Furthermore, schwannomas also commonly develop in other cranial nerves, dorsal root ganglia and peripheral nerves. These tumors are a major cause of morbidity and mortality, and medical therapies to treat them are limited. Animal models that accurately recapitulate the full anatomical spectrum of human NF2-related schwannomas, including the characteristic functional deficits in hearing and balance associated with cranial nerve VIII tumors, would allow systematic evaluation of experimental therapeutics prior to clinical use. Here, we present a genetically engineered NF2 mouse model generated through excision of the Nf2 gene driven by Cre expression under control of a tissue-restricted 3.9kbPeriostin promoter element. By 10 months of age, 100% of Postn-Cre; Nf2(flox/flox) mice develop spinal, peripheral and cranial nerve tumors histologically identical to human schwannomas. In addition, the development of cranial nerve VIII tumors correlates with functional impairments in hearing and balance, as measured by auditory brainstem response and vestibular testing. Overall, the Postn-Cre; Nf2(flox/flox) tumor model provides a novel tool for future mechanistic and therapeutic studies of NF2-associated schwannomas.
© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25113746      PMCID: PMC4262489          DOI: 10.1093/hmg/ddu414

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  30 in total

1.  The mouse slalom mutant demonstrates a role for Jagged1 in neuroepithelial patterning in the organ of Corti.

Authors:  H Tsai; R E Hardisty; C Rhodes; A E Kiernan; P Roby; Z Tymowska-Lalanne; P Mburu; S Rastan; A J Hunter; S D Brown; K P Steel
Journal:  Hum Mol Genet       Date:  2001-03-01       Impact factor: 6.150

2.  Postural and locomotor control in normal and vestibularly deficient mice.

Authors:  P-P Vidal; L Degallaix; P Josset; J-P Gasc; K E Cullen
Journal:  J Physiol       Date:  2004-07-08       Impact factor: 5.182

3.  CXCR4/CXCL12 mediate autocrine cell- cycle progression in NF1-associated malignant peripheral nerve sheath tumors.

Authors:  Wei Mo; Jian Chen; Amish Patel; Liang Zhang; Vincent Chau; Yanjiao Li; Woosung Cho; Kyun Lim; Jing Xu; Alexander J Lazar; Chad J Creighton; Svetlana Bolshakov; Renée M McKay; Dina Lev; Lu Q Le; Luis F Parada
Journal:  Cell       Date:  2013-02-21       Impact factor: 41.582

4.  Auditory brainstem volume-conducted responses: origins in the laboratory mouse.

Authors:  K R Henry
Journal:  J Am Aud Soc       Date:  1979 Mar-Apr

5.  Nf1 and Gmcsf interact in myeloid leukemogenesis.

Authors:  R A Birnbaum; A O'Marcaigh; Z Wardak; Y Y Zhang; G Dranoff; T Jacks; D W Clapp; K M Shannon
Journal:  Mol Cell       Date:  2000-01       Impact factor: 17.970

6.  Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2.

Authors:  M Giovannini; E Robanus-Maandag; M van der Valk; M Niwa-Kawakita; V Abramowski; L Goutebroze; J M Woodruff; A Berns; G Thomas
Journal:  Genes Dev       Date:  2000-07-01       Impact factor: 11.361

7.  Innate neural stem cell heterogeneity determines the patterning of glioma formation in children.

Authors:  Da Yong Lee; Scott M Gianino; David H Gutmann
Journal:  Cancer Cell       Date:  2012-07-10       Impact factor: 31.743

8.  Occurrence and characterization of peripheral nerve involvement in neurofibromatosis type 2.

Authors:  A D Sperfeld; C Hein; J M Schröder; A C Ludolph; C O Hanemann
Journal:  Brain       Date:  2002-05       Impact factor: 13.501

9.  Comparative pathology of nerve sheath tumors in mouse models and humans.

Authors:  Anat O Stemmer-Rachamimov; David N Louis; Gunnlaugur P Nielsen; Cristina R Antonescu; Alexander D Borowsky; Roderick T Bronson; Dennis K Burns; Pascale Cervera; Margaret E McLaughlin; Guido Reifenberger; Michael C Schmale; Mia MacCollin; Richard C Chao; Karen Cichowski; Michel Kalamarides; Shanta M Messerli; Andrea I McClatchey; Michiko Niwa-Kawakita; Nancy Ratner; Karlyne M Reilly; Yuan Zhu; Marco Giovannini
Journal:  Cancer Res       Date:  2004-05-15       Impact factor: 12.701

10.  Mechanisms of hearing loss in neurofibromatosis type 2.

Authors:  Ashok R Asthagiri; Raul A Vasquez; John A Butman; Tianxia Wu; Keaton Morgan; Carmen C Brewer; Kelly King; Chris Zalewski; H Jeffrey Kim; Russell R Lonser
Journal:  PLoS One       Date:  2012-09-26       Impact factor: 3.240

View more
  30 in total

1.  Nf2 Mutation in Schwann Cells Delays Functional Neural Recovery Following Injury.

Authors:  Kristy Truong; Iram Ahmad; J Jason Clark; Alison Seline; Tyler Bertroche; Brian Mostaert; Douglas J Van Daele; Marlan R Hansen
Journal:  Neuroscience       Date:  2018-02-03       Impact factor: 3.590

2.  Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.

Authors:  Lai Man Natalie Wu; Yaqi Deng; Jincheng Wang; Chuntao Zhao; Jiajia Wang; Rohit Rao; Lingli Xu; Wenhao Zhou; Kwangmin Choi; Tilat A Rizvi; Marc Remke; Joshua B Rubin; Randy L Johnson; Thomas J Carroll; Anat O Stemmer-Rachamimov; Jianqiang Wu; Yi Zheng; Mei Xin; Nancy Ratner; Q Richard Lu
Journal:  Cancer Cell       Date:  2018-02-12       Impact factor: 31.743

3.  Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.

Authors:  Jennifer Kersigo; Lintao Gu; Linjing Xu; Ning Pan; Sarath Vijayakuma; Timothy Jones; Seiji B Shibata; Bernd Fritzsch; Marlan R Hansen
Journal:  Laryngoscope       Date:  2020-05-21       Impact factor: 3.325

4.  Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.

Authors:  Robert F Hennigan; Jonathan S Fletcher; Steven Guard; Nancy Ratner
Journal:  Sci Signal       Date:  2019-04-23       Impact factor: 8.192

Review 5.  CNS Tumors in Neurofibromatosis.

Authors:  Jian Campian; David H Gutmann
Journal:  J Clin Oncol       Date:  2017-06-22       Impact factor: 44.544

6.  A Xenograft Model of Vestibular Schwannoma and Hearing Loss.

Authors:  Christine T Dinh; Olena Bracho; Christine Mei; Esperanza Bas; Cristina Fernandez-Valle; Fred Telischi; Xue-Zhong Liu
Journal:  Otol Neurotol       Date:  2018-06       Impact factor: 2.311

Review 7.  Cochlear histopathology in human genetic hearing loss: State of the science and future prospects.

Authors:  Krishna Bommakanti; Janani S Iyer; Konstantina M Stankovic
Journal:  Hear Res       Date:  2019-08-19       Impact factor: 3.208

8.  Fluorescent Detection of Merlin-deficient Schwann Cells and Primary Human Vestibular Schwannoma Cells Using Sodium Fluorescein.

Authors:  Enrique R Perez; Olena Bracho; Liliana Ein; Mikhaylo Szczupak; Paula V Monje; Cristina Fernandez-Valle; Abdulaziz Alshaiji; Michael Ivan; Jacques Morcos; Xue-Zhong Liu; Michael Hoffer; Adrien Eshraghi; Simon Angeli; Fred Telischi; Christine T Dinh
Journal:  Otol Neurotol       Date:  2018-09       Impact factor: 2.311

9.  A proteasome-resistant fragment of NIK mediates oncogenic NF-κB signaling in schwannomas.

Authors:  Jeffrey R Gehlhausen; Eric Hawley; Benjamin Mark Wahle; Yongzheng He; Donna Edwards; Steven D Rhodes; Jacquelyn D Lajiness; Karl Staser; Shi Chen; Xianlin Yang; Jin Yuan; Xiaohong Li; Li Jiang; Abbi Smith; Waylan Bessler; George Sandusky; Anat Stemmer-Rachamimov; Timothy J Stuhlmiller; Steven P Angus; Gary L Johnson; Grzegorz Nalepa; Charles W Yates; D Wade Clapp; Su-Jung Park
Journal:  Hum Mol Genet       Date:  2019-02-15       Impact factor: 6.150

10.  Anti-VEGF treatment improves neurological function and augments radiation response in NF2 schwannoma model.

Authors:  Xing Gao; Yingchao Zhao; Anat O Stemmer-Rachamimov; Hao Liu; Peigen Huang; ShanMin Chin; Martin K Selig; Scott R Plotkin; Rakesh K Jain; Lei Xu
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.